# US 2024/0189346 A1 · Methods for raising nitric oxide and reduction of uric acid > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 2024/0189346 A1 - Document ID: US20240189346A1 - Status: Published application - Kind: A1 - Application number: 18/583,657 - Filed: 2024-02-21 - Published: 2024-06-13 - Earliest claimed: 2022-01-18 - Assignees: Azulent, LLC - Applicants: Azulent, LLC - Inventors: Eugene P. PITTZ; Chen CHEN - Web page: https://patentgrep.com/patent/US20240189346A1 ## CPC - A61K 9/0073: {Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy; (nasal sprays A61K9/0043; inhalation of vapours of volatile or heated drugs, e.g. essential oils or nicotine, A61K9/007; devices A61M)} - A61K 33/06: Aluminium, calcium or magnesium; Compounds thereof {, e.g. clay} - A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration} - A61K 31/522: having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir - A61K 33/00: Medicinal preparations containing inorganic active ingredients - A61K 36/185: Magnoliopsida (dicotyledons) - A61K 36/734: Crataegus (hawthorn) - A61K 36/742: {Coffea, e.g. coffee} - A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca - C01B 21/24: Nitric oxide (NO) {(C01B21/203 takes precedence)} - A61K 9/0002: {Galenical forms characterised by the drug release technique; Application systems commanded by energy} - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - C01B: NON-METALLIC ELEMENTS; COMPOUNDS THEREOF; {METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C} ## Abstract A method of accelerating the production of nitric oxide (NO) can include co-administering a generator of H2 with a generator of nitric oxide (NO) as a formulation to a subject. The generator of H2 includes elemental magnesium metal powder and the generator of NO is a nitrate, while the formulation is also free of amino acids. ## Claims ### Claim 1 A method of accelerating production of nitric oxide (NO) by co-administering a generator of H2 with a generator of nitric oxide (NO) as a formulation to a subject, wherein the generator of H2 includes elemental magnesium metal powder and the generator of NO is a nitrate, and the formulation is free of amino acids. ### Claim 2 (depends on 1) The method according to claim 1, wherein the magnesium metal powder is in the formulation at a concentration of 0.01 to 50% w/w. ### Claim 3 (depends on 1) The method according to claim 1, wherein the generator of NO is present at a concentration of 0.01-50% w/w. ### Claim 4 (depends on 1) The method of claim 1, wherein the generator of NO is one or more of a salt of nitrate, a salt of nitrite, beet juice powder, celery powder, herbal powder, and vegetable powder containing nitrates. ### Claim 5 (depends on 4) The method of claim 4, further comprising ingesting a high fiber diet, which generates molecular hydrogen, before the co-administering. ### Claim 6 (depends on 5) The method of claim 5, wherein the high fiber diet contains fibers at a total content of 3-60 grams and wherein the fibers include one or more of beans, legumes, whole grains, cereals, vegetables, fruits, nuts, seeds, cellulose, hemicellulose, psyllium, resistant starch, inulin, wheat dextrin, oligosaccharides, pectin, glucomannan, xanthan gum, carrageenan, and combinations thereof. ### Claim 7 (depends on 6) The method of claim 6, wherein the high fiber diet is ingested 2-8 hours before ingestion of the generator of NO. ### Claim 8 (depends on 1) The method of claim 1, where the generator of H2 further includes hydrogen-infused water. ### Claim 9 (depends on 1) The method of claim 1, where the generator of H2 further includes H2 gas which is administered by inhalation. ### Claim 10 (depends on 1) The method of claim 1, wherein the generator of H2 further includes ascorbic acid and results in increases in salivary nitric oxide test strip measurements by up to 350%. ### Claim 11 (depends on 10) The method of claim 10, wherein ascorbic acid is present in the formulation at 0.001-75% w/w. ### Claim 12 (depends on 10) The method of claim 10, wherein the magnesium metal powder is present in the formulation at 0.01-50% w/w. ### Claim 13 (depends on 10) The method of claim 10, further comprising a modulator of eNOs (endothelial nitric oxide synthase) present in the formulation up to 25% w/w. ### Claim 14 (depends on 13) The method of claim 13, wherein the modulator of eNOS includes at least one of salts of nitrate, salts nitrites, acetyl salicylic acid, BH4, folic acid, vitamin B1, vitamin B6, vitamin B12, vitamin D3, magnesium, and zinc. ### Claim 15 (depends on 1) The method of claim 1, wherein the co-administering of the generator of H2 is sufficient to lower a blood level of uric acid. ### Claim 16 (depends on 15) The method of claim 15, wherein the salivary level of uric acid that is correlated to blood uric acid is determined. ### Claim 17 (depends on 1) The method of claim 1, wherein the formulation is in a form of capsules, tablets, powders, liquids, or hydrogels. ### Claim 18 (depends on 1) The method of claim 1, wherein the generator of H2 is sufficient to reduce pain due to inflammation affected by uric acid. ### Claim 19 (depends on 18) The method of claim 18, wherein up to 50% ascorbic acid is added to the formulation to further reduce uric acid. ### Claim 20 (depends on 18) The method of claim 18, wherein the formulation further comprises one or more of allopurinol, corticosteroids, and colchicine. ### Claim 21 (depends on 18) The method of claim 18, wherein the subject is identified prior to the co-administering as having one or more diseases including cardiovascular disease, bone and joint deterioration, gouty arthritis, kidney disease, Alzheimer's disease, and vascular dementia.